Neuroprotection in Huntington??s disease: a 2-year study on minocycline
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD), a relentlessly progressive neurodegenerative disorder, is characterized by a clinical triad of psychiatric, cognitive and motor disturbances. The antibiotic minocycline, a caspase inhibitor exhibiting antiapoptotic properties, has been shown to prolong survival in the transgenic mouse model of HD. We administrated minocycline to 14 patients with genetically confirmed HD. The patients were psychiatrically, neurologically and neuropsychologically evaluated at baseline, and after 6 and 24 months of treatment, using the Unified HD Rating Scale and a neuropsychological test battery. After 12 months, three patients were lost to follow-up so that 11 patients were analysed at the endpoint. Minocycline was well tolerated. Unlike the expected natural course of HD, patients exhibited stabilization in general motor and neuropsychological function at endpoint, after improving in the first 6 months. Moreover, we found a significant amelioration of psychiatric symptoms that was not apparent after the first 6 months. In detail, the Mini-Mental State Examination, the Total Motor Score, the Total Functional Capacity Scale and the Independence Scale, as the most prominent scales in HD, were stabilized after 3 years of treatment. Our results confirm previous animal studies and indicate a neuroprotective effect of this agent in HD. A long-term, double-blind, placebo-controlled trial appears highly warranted for definitively establishing the value of minocycline in HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892 · cited 1×
“This pattern of action is a familiar finding for antidementia drugs in Alzheimer’s disease, delaying disease progression (Courtney et al., 2004).”
BackgroundNeuropsychiatric aspects of Huntington’s disease.
Paulsen, J. S. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.3.310 · Cited by 486 · cited 4×
“Symptoms range from mild to severe and are generally unrelated to dementia and chorea (Paulsen et al., 2001).”
BackgroundInfluentialRate of functional decline in Huntington’s disease
Marder, K., Zhao, H., Myers, R. H., Cudkowicz, M., Kayson, E., Kieburtz, K., Orme, C., Paulsen, J., Penney, J. B., Siemers, E., et al. (2000) · Neurology · doi:10.1212/wnl.54.2.452 · Cited by 362
Cited by
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Kern, T. S. (2007) · Journal of Diabetes Research · doi:10.1155/2007/95103 · Cited by 614
Tabrizi, S. J., Reilmann, R., Roos, R. A., Durr, A., Leavitt, B., Owen, G., Jones, R., Johnson, H., Craufurd, D., Hicks, S. L., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70263-0 · Cited by 547
Microglia Biology in Health and Disease
Garden, G. A., & Möller, T. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9015-5 · Cited by 496
Minocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
Metadata
- Authors
- Bonelli, R. M., H??dl, A. K., Hofmann, P., & Kapfhammer, H.-P.
- Venue
- International Clinical Psychopharmacology
- Published
- 2004-11
- Volume
- 19
- Issue
- 6
- Pages
- 337-342
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1966815691
- Cited by
- 108
- References
- 3
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotection in Huntington??s disease: a 2-year study on minocycline. https://app.cochat.ai/papers/10.1097/00004850-200411000-00004
- The paper
- Bonelli, R. M., H??dl, A. K., Hofmann, P., & Kapfhammer, H.-P. (2004). Neuroprotection in Huntington??s disease: a 2-year study on minocycline. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200411000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.